← Back to Search

CAR T-cell Therapy

CAR T-cell Therapy for Multiple Sclerosis

Phase 1

Recruiting

Led By Jeffrey Dunn, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient is ≥ 18 years old, and ≤55 years of age, at time of screening visit

Progressive MS by 2014 Lublin MS phenotypic criteria

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial will use gene therapy to treat MS, testing if a modified immune cell can stop or slow the progression of the disease.

Who is the study for?

This trial is for adults aged 18-55 with progressive forms of Multiple Sclerosis, as per the McDonald and Lublin criteria. Participants must have certain antibody levels, normal organ function, no recent investigational drugs or specific treatments, and agree to contraception if applicable.Check my eligibility

What is being tested?

The study tests KYV-101 anti-CD19 CAR-T cell therapy following a standard lymphodepletion regimen in patients with non-relapsing and progressive MS. It aims to evaluate the safety and effectiveness of this innovative treatment approach.See study design

What are the potential side effects?

Potential side effects may include immune system reactions, infusion-related responses, changes in blood counts leading to increased infection risk or bleeding problems, fatigue, and possible impacts on liver or kidney function.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am between 18 and 55 years old.

Select...

My MS is getting worse according to the 2014 Lublin criteria.

Select...

I have antibodies against the Epstein-Barr virus.

Select...

My blood tests show normal immune and marrow function.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Frequency of dose limiting toxicities at each dose level

Secondary outcome measures

Incidence of adverse events (AEs) including clinical tolerance and laboratory abnormalities

To characterize the pharmacodynamics (PD)

To characterize the pharmacokinetics (PK)

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: KYV-101 CAR-T cells with lymphodepletion conditioningExperimental Treatment2 Interventions

Dosing with KYV-101 CAR T cells

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,395 Previous Clinical Trials

17,341,338 Total Patients Enrolled

3 Trials studying Multiple Sclerosis

197 Patients Enrolled for Multiple Sclerosis

Kyverna TherapeuticsIndustry Sponsor

5 Previous Clinical Trials

228 Total Patients Enrolled

1 Trials studying Multiple Sclerosis

120 Patients Enrolled for Multiple Sclerosis

Jeffrey Dunn, MDPrincipal InvestigatorStanford University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining openings to participate in this trial?

"Data hosted on clinicaltrials.gov reveals that this trial, which was first posted in December of 2023, is not currently recruiting patients. However, there are 557 other studies actively searching for participants at the moment."

Answered by AI

Is there any possibility for me to partake in this research endeavor?

"Entry into this medical trial is limited to individuals suffering from multiple sclerosis and aged between 18 and 55. The total number of enrollees sought is 12."

Answered by AI

Are individuals who are over 80 years old precluded from participating in this experiment?

"According to the trial's criteria, only individuals aged 18-55 are eligible. For those wishing to participate who fall outside of that age range, there are 38 studies for minors and 408 for seniors."

Answered by AI